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January 19, 2010:255–69rials had a highly selected population of diabetic patients, which may
ot be representative of the risk for cardiovascular events in the
eneral diabetic population.
Perhaps more importantly, the method for development of
UC is rigorous and does not permit alteration of the final scores
nd classification by the technical (rating) panel. Additionally, the
UC do not state that testing “must” be performed, only that it is
easonable given the clinical scenario and the available medical
nowledge/experience. AUC are therefore not equivalent to a
lass I clinical practice guideline.
Although the COURAGE nuclear substudy was underpowered
o detect differences in treatment approaches, those subjects who
xperienced a reduction of ischemia on single-positron emission
omputed tomography myocardial perfusion imaging had a supe-
ior outcome, although this difference was lost when further risk
djusted. Therefore, we agree with the opinion of Dr. Sethi and
olleagues that “routine RNI can be of use, if we can identify a
ubgroup of asymptomatic patients . . . who can benefit from
evascularization.” This thereby allows the indication to be con-
idered “appropriate” or reasonable in the parlance of AUC.
We agree that, in light of the newer trials, it may not be
ccurate to place patients with only the risk factor of diabetes
nto the high-risk category. However, based on available infor-
ation, we believe that the rating by the technical panel was
easonable. We await additional information on the best way for
isk assessment of patients and will certainly consider revising
he AUC as new evidence becomes available. Thank you for
our thoughtful comments.
Robert C. Hendel, MD, Chair,
Writing Group for RNI Appropriate Use Criteria
ichael J. Wolk, MD, Chair,
Appropriate Use Criteria Task Force
Director of Cardiac Imaging
niversity of Miami Miller School of Medicine
120 Northwest 14th Street
uite 118
iami, Florida 33136
-mail: rhendel.cardio@yahoo.com
doi:10.1016/j.jacc.2009.09.026
EFERENCE
. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/
AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for
cardiac radionuclide imaging: a report of the American College of
Cardiology Foundation Appropriate Use Criteria Task Force, the
American Society of Nuclear Cardiology, the American College of
Radiology, the American Heart Association, the American Society of
Echocardiography, the Society of Cardiovascular Computed Tomogra-
phy, the Society for Cardiovascular Magnetic Resonance, and the
Society of Nuclear Medicine. J Am Coll Cardiol 2009;53:2201–29.
. Young LH, Wackers FJ, Chyun DA, et al., for the DIAD Investigators.
Cardiac outcomes after screening for asymptomatic coronary artery
disease in patients with type 2 diabetes. The DIAD study: a randomized
controlled trial. JAMA 2009;301:1547–55.
. Frye RL, August P, Brooks MM, et al., for the BARI 2D Study Group.
A randomized trial of therapies for type 2 diabetes and coronary artery
disease. N Engl J Med 2009;360:2503–15.
. Boden WE, O’Rourke RA, Teo KK, et al., for the COURAGE Trial
Research Group. Optimal medical therapy with or without PCI for
stable coronary disease. N Engl J Med 2007;356:1503–16. ohe Need for Sex-Specific
ata Prior to Food and Drug
dminstration Approval
e read with great interest the recent paper by Hsich and Piña (1)
hat examined the many aspects in which we lack data for heart
ailure in women. We wholeheartedly agree that heart failure trials
ust include more women and must provide more sex-specific
ata, and we further believe that there must be evidence of net
enefit in women before Food and Drug Administration approval
or devices to be implanted in critically ill patients.
For example, the authors mention that the recent approval of
he Thoratec HeartMate II (Thoratec Corporation, Pleasanton,
alifornia) will allow more implantation of ventricular assist
evices in women and will provide prospective data through the
nteragency Registry for Mechanically Assisted Circulation regis-
ry. However, the device was approved based on data from only 44
omen, who constituted 23% of the overall study population. The
ood and Drug Administration’s Summary of Safety and Effec-
iveness Data for this device noted that the small number of
omen “makes it difficult to draw any conclusions regarding
ifferences in safety profile of the device between men and women”
2). Even so, it is worrisome that women had an increased rate of
ome important adverse events, including a 3-fold higher incidence
f stroke (18% vs. 6% in men) and trends toward a higher
ncidence of bleeding and infection events. These risks may be
orthwhile if the device had proven benefit, but it is concerning
hat the device’s success rate did not meet the pre-specified end
oint for success (2).
Therefore, we agree with the authors that a post-approval
egistry to collect data on outcomes in women for this device will
rovide needed information. However, requiring evidence of
enefit in women before Food and Drug Administration approval
or implanted devices would be an important step toward ensuring
hat we are providing safe care for women with heart failure.
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e appreciate the insightful remarks of Drs. Dhruva and Redberg
n our paper (1). We agree that to improve health care for women,
